Editorial brief continued
company at approximately $
- The deal centers on Apogee's lead drug candidate, zumilokibart, an antibody targeting IL-13, a protein that drives inflammatory conditions including atopic dermatitis — the most common form of eczema — and asthma.
- In a Phase 2 trial, roughly two-thirds of patients on treatment achieved significant skin clearance at 16 weeks, the company said.
Event:
Primary source published:
Catalayer published: · Modified:
What happened
AbbVie acquires Apogee Therapeutics for $10.9 billion Quartz · NurPhoto / Getty Images Cris Tolomia Mon, June 22, 2026 at 9:32 PM GMT+9 2 min read ABBV APGE AbbVie agreed to acquire Apogee Therapeutics for $135.11 per share in cash, valuing the clinical-stage biotechnology company at approximately $10.9 billion, the companies said Monday. Both boards have approved the transaction, which is expected to close in the third quarter of 2026, pending regulatory approval and a vote by Apogee shareholders. The deal centers on Apogee's lead drug candidate, zumilokibart, an antibody targeting IL-13, a protein that drives inflammatory conditions including atopic dermatitis — the most common form of eczema — and asthma.
Primary evidence
Primary reporting sourced from Quartz (https://finance.yahoo.com/healthcare/articles/abbvie-acquires-apogee-therapeutics-10-123213044.html). All transaction figures, dates, and statements cross-referenced against wire feeds.
Why it matters
As a significant MERGER ACQUISITION development, this event shifts institutional capital allocations across pharma and directly alters operating assumptions for $ABBV, $XLV.
Transmission mechanisms
Market transmission operates through supply chain linkages, cost-of-capital adjustments, and sector re-rating across pharma, impacting near-term valuation multiples for $ABBV, $XLV.
Uncertainties and competing interpretations
Key execution risks include duration delays, regulatory scrutiny across pharma, and whether secondary price discovery sustains support for $ABBV, $XLV amid macro rotation.
What to monitor next
Key upcoming milestones include official regulatory disclosures, next quarterly SEC filings, and volume-weighted institutional accumulation in $ABBV, $XLV.
[S1] Quartz Disclosure & Report
Original factual event report published via Quartz (https://finance.yahoo.com/healthcare/articles/abbvie-acquires-apogee-therapeutics-10-123213044.html). Verified factual financial record with zero synthetic quotes.
Track Real-Time Market Intelligence & Corporate Catalysts
Catalayer News transforms corporate filings, earnings disclosures, and market events into deterministic intelligence signals.